Tifacogin (Chiron Corp/Pharmacia Corp).
Bibliographic record
Abstract
Tifacogin is a recombinant tissue factor pathway inhibitor (rTFPI) under development by Pharmacia Corp (formerly GD Searle) and Chiron as a potential treatment for sepsis. The product is in phase III trials [406208]. In July 2000, Pharmacia anticipated regulatory filings in 2002 [374505]. Chiron and Searle conducted research on TFPI independently in the early 1990s and entered an agreement to collaborate on the development, manufacturing and marketing of the compound in 1994, granting each other licenses on the patents concerned with TFPI [224098]. Searle (Monsanto Co) first disclosed recombinant TFPI in the associated patent, US-05212091. Unlike natural TFPI, however, it possessed an N-terminal alanine and the expression method using E coli did not always yield entirely homologous protein. A method for expressing genuine TFPI in yeast is disclosed in Chiron's patent WO-09604377. Patents for methods of treating sepsis with TFPI were claimed independently in two patents from Cetus Oncology (Chiron; WO-09324143) and Searle (WO-09325230). The discovery research of TFPI was conducted by Searle in collaboration with Washington University [224098]. Washington University holds two patents, EP-00563023 and WO-09604378, which claim the use of TFPI for the inhibition of microvascular thrombosis and reperfusion injury, respectively. Analysts at Lehman Brothers predicted in December 2001, that there was a 50% probability of the drug making it to market, with peak sales potential of 500 million US dollars in 2003 [434768].
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.075 | 0.035 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".